Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients
Hirofumi Mukai, Chikako Shimizu, Norikazu Masuda, et al.
International Journal of Clinical Oncology (2018) Vol. 24, Iss. 3, pp. 274-287
Open Access | Times Cited: 62

Showing 1-25 of 62 citing articles:

Regulating tumor suppressor genes: post-translational modifications
Ling Chen, Shuang Liu, Yongguang Tao
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 324
Cell-free DNA analysis in current cancer clinical trials: a review
Mireya Cisneros-Villanueva, Lizbett Hidalgo Pérez, M. Rios-Romero, et al.
British Journal of Cancer (2022) Vol. 126, Iss. 3, pp. 391-400
Open Access | Times Cited: 130
Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice
Angela DeMichele, Massimo Cristofanilli, Adam Brufsky, et al.
Breast Cancer Research (2021) Vol. 23, Iss. 1
Open Access | Times Cited: 104
Targeted therapy for breast cancer: An overview of drug classes and outcomes
Aaron T. Jacobs, Diana Martinez Castaneda-Cruz, Mark M. Rose, et al.
Biochemical Pharmacology (2022) Vol. 204, pp. 115209-115209
Open Access | Times Cited: 85
Drug repurposing for breast cancer therapy: Old weapon for new battle
Sadhna Aggarwal, Sumit Singh Verma, Sumit Aggarwal, et al.
Seminars in Cancer Biology (2019) Vol. 68, pp. 8-20
Open Access | Times Cited: 127
Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib
Stefanie L. Groenland, Alejandra Martínez-Chávez, Marloes G. J. van Dongen, et al.
Clinical Pharmacokinetics (2020) Vol. 59, Iss. 12, pp. 1501-1520
Closed Access | Times Cited: 70
Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer
Yuan Yuan, Jin Sun Lee, Susan E. Yost, et al.
European Journal of Cancer (2021) Vol. 154, pp. 11-20
Open Access | Times Cited: 58
Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: Primary results from PALOMA-4
Binghe Xu, Xichun Hu, Wěi Li, et al.
European Journal of Cancer (2022) Vol. 175, pp. 236-245
Open Access | Times Cited: 46
Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study
Seock-Ah Im, Hirofumi Mukai, In Hae Park, et al.
Journal of Global Oncology (2019), Iss. 5, pp. 1-19
Open Access | Times Cited: 66
Which test for crossing survival curves? A user’s guideline
Ina Dormuth, Tiantian Liu, Jin Xu, et al.
BMC Medical Research Methodology (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 37
Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure
Rossana Roncato, Elena Peruzzi, Lorenzo Gerratana, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 164, pp. 114906-114906
Open Access | Times Cited: 20
Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2– advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study)
Shigenori E. Nagai, Masaya Hattori, Tetsuhiro Yoshinami, et al.
Breast Cancer (2025)
Open Access
Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130)
Hiroji Iwata, Kenichi Inoue, Koji Kaneko, et al.
Japanese Journal of Clinical Oncology (2019) Vol. 49, Iss. 12, pp. 1083-1091
Open Access | Times Cited: 41
Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study
Tetsuhiro Yoshinami, Shigenori E. Nagai, Masaya Hattori, et al.
Breast Cancer (2024) Vol. 31, Iss. 4, pp. 621-632
Open Access | Times Cited: 3
Disparities in receipt of 1-st line CDK4/6 inhibitors with endocrine therapy for treatment of hormone receptor positive, HER2 negative metastatic breast cancer in the real-world setting
Asal Pilehvari, Gretchen Kimmick, Wen You, et al.
Breast Cancer Research (2024) Vol. 26, Iss. 1
Open Access | Times Cited: 3
Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer
Kenji Tamura
Japanese Journal of Clinical Oncology (2019) Vol. 49, Iss. 11, pp. 993-998
Open Access | Times Cited: 29
Establishment of an analytical method for simultaneous quantitation of CDK4/6 inhibitors, aromatase inhibitors, and an estrogen receptor antagonist in human plasma using LC-ESI-MS/MS
Yu Sato, Kensuke Shigeta, Tensei Hirasawa, et al.
Journal of Chromatography B (2021) Vol. 1173, pp. 122655-122655
Open Access | Times Cited: 20
Clinical and Genotypic Insights Into Higher Prevalence of Palbociclib Associated Neutropenia in Asian Patients
Jiun‐I Lai, Ting-Hao Kuo, Kuan‐Jung Huang, et al.
The Oncologist (2023) Vol. 29, Iss. 4, pp. e455-e466
Open Access | Times Cited: 8
Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3
Hiroji Iwata, Yoshiko Umeyama, Yuan Liu, et al.
The Oncologist (2021) Vol. 26, Iss. 7, pp. e1143-e1155
Open Access | Times Cited: 20
Ribociclib Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Analysis of Neutrophils in Cancer Patients
Yasong Lu, Shu Yang, Yu‐Yun Ho, et al.
The Journal of Clinical Pharmacology (2021) Vol. 61, Iss. 8, pp. 1054-1068
Closed Access | Times Cited: 19
BRD4 Inhibition as a Strategy to Prolong the Response to Standard of Care in Estrogen Receptor-Positive Breast Cancer
Ahmed M. Elshazly, Melanie M. Sinanian, Victoria Neely, et al.
Cancers (2023) Vol. 15, Iss. 16, pp. 4066-4066
Open Access | Times Cited: 7
CDK4/6 inhibitors plus endocrine therapy vs. placebo plus endocrine therapy for HR+/HER2- advanced breast cancer: a phase III RCTs based meta-analysis
Cailu Luo, Kunlin Yu, Xiaodan Luo, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy
Kenichi Inoue, Norikazu Masuda, Hiroji Iwata, et al.
Breast Cancer (2021) Vol. 28, Iss. 5, pp. 1038-1050
Open Access | Times Cited: 17
Palbociclib and letrozole in hormone-receptor positive advanced breast cancer: Predictive response and prognostic factors
Khalil El Gharib, Walid Macaron, Joseph Kattan, et al.
Current Problems in Cancer (2022) Vol. 46, Iss. 3, pp. 100859-100859
Closed Access | Times Cited: 11
Real-World Outcomes of Treating Advanced Breast Cancer Patients With Palbociclib: A Multicenter Retrospective Cohort Study in Japan—The KBCOG-14 Study
Nina Odan, Yuichiro Kikawa, Hajime Matsumoto, et al.
Breast Cancer Basic and Clinical Research (2020) Vol. 14
Open Access | Times Cited: 16
Page 1 - Next Page

Scroll to top